



Press Release

For Immediate Release

**HKSTP and WuXi XDC Join Forces to Promote
Development of Bioconjugate Drug Industry in Hong Kong**

- HKSTP and WuXi XDC signed a collaboration framework agreement to jointly promote the establishment of a contract research, development and manufacturing organisation (CRDMO) value chain in Hong Kong.
- HKSTP Park companies will leverage WuXi XDC's one-stop service platform to develop Antibody Drug Conjugate (ADC) and other bioconjugates.
- WuXi XDC will support the advancement of the bioconjugation industry in Hong Kong by providing consultation and training to local enterprises.

Hong Kong, 18 October 2023 – Hong Kong Science and Technology Parks Corporation (HKSTP) and WuXi XDC, a leading global contract research, development and manufacturing organisation (CRDMO) specialised in the bioconjugate market, signed a collaboration framework agreement to jointly advance the establishment of a CRDMO value chain in Hong Kong.

The partnership will drive the development of ADC and other bioconjugates in Hong Kong leveraging WuXi XDC's comprehensive services and capabilities. Both parties will enhance trainings and collaborations between industry, academic and research institutions with an aim of boosting the biotechnology ecosystem in Hong Kong.

HKSTP Park companies will have access to WuXi XDC's integrated, one-stop bioconjugate platform for drug discovery, development, and analytical services. WuXi XDC will provide consultation and training to Hong Kong biotechnology companies and research institutions, accelerating the translation of scientific research results into market-ready products.

HKSTP and WuXi XDC will deepen the collaborations by sharing resources and organising engagement activities. A roadmap will be set out for propelling the establishment of a CRDMO value chain in Hong Kong, which will in turn speed up the drug development process and shorten the time to market.

Mr Albert Wong, CEO of HKSTP, said, "As the largest technology research and development (R&D) base and incubator in Hong Kong, HKSTP offers integrated state-of-the-art infrastructure and supporting services to the I&T ecosystem. We are excited to work with WuXi XDC to facilitate companies in terms of technology transfer and market expansion. By leveraging the strengths of both sides, we look forward to further enhancing the biotechnology ecosystem, paving the way for Hong Kong's development into an international innovation and technology hub."

Dr Jimmy Li, CEO of WuXi XDC, said, "We are pleased to collaborate with HKSTP in supporting local biotech companies with our one-stop platform, leading industry know-how and high-quality services. Hong Kong Science Park is a hotbed for biotechnology with innovation capabilities. We look forward to cementing our partnership with HKSTP, enabling the development of the bioconjugate industry and positively impacting patients worldwide."



As a global leading CRDMO focusing on the bioconjugate drug market, WuXi XDC provides interdisciplinary R&D services. ADC is a targeted drug. The principle behind them is to covalently link (also known as “conjugate”) cytotoxic small molecule drugs to antibodies through unique chemical linkers to kill target cells. In addition to tumor treatment, ADC drugs are also widely used in treating autoimmune diseases, infectious diseases and metabolic disorders, among others.



Photo: Dr Grace Lau, Head of Institute for Translational Research of HKSTP (third from right) and Dr Jimmy Li, CEO of WuXi XDC (fourth from left) signed a collaboration framework agreement to jointly promote the establishment of a contract research, development and manufacturing organisation (CRDMO) value chain in Hong Kong.

###

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that supported over 10 unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,400 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long. The three InnoParks are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.



Through our infrastructure, services, expertise, and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong's international I&T hub status as a launchpad for growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at www.hkstp.org.

About WuXi XDC

WuXi XDC is a leading global CRDMO focused on the ADC and broader bioconjugate market. It is a joint venture between WuXi Biologics and WuXi STA, providing end-to-end contract research, development and manufacturing services for bioconjugates, including antibody drug conjugates (ADCs). Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline. As of June 2023, 110 on-going integrated projects are under development at WuXi XDC, including 47 post-IND bioconjugate projects, among which 16 projects are in phase II/III. For more information about WuXi XDC, please visit: www.wuxixdc.com

Media Contact:

Hong Kong Science and Technology Parks Corporation

Terry Lam

Tel: +852 2629 6769

Email: terry.lam@hkstp.org

Edelman Public Relations

Chase Xu

Tel: +852 2837 4718/ 6010 9246

Email: Chase.Xu@edelman.com /

Edelmanhkstppr@edelman.com